
American Vanguard Corporation, through its subsidiaries, develops, manufactures, and markets specialty chemicals for agricultural, commercial, and consumer uses in the United States and internationally. It manufactures and formulates chemicals, including insecticides, fungicides, herbicides, molluscicides, soil health, plant nutrition, growth regulators, and soil fumigants in liquid, powder, and granular forms for crops, turf and ornamental plants, and human and animal health protection. The company also markets, sells, and distributes end-use chemical and biological products for crop applications; and distributes chemicals for turf and ornamental markets. It distributes its products through national distribution companies, and buying groups or co-operatives; and through sales offices, sales force executives, sales agents, and wholly owned distributors. The company was incorporated in 1969 and is headquartered in Newport Beach, California.
American Vanguard Corporation trades as AVD on NYSE. The company is classified in Basic Materials / Agricultural Inputs and reports in USD.
The current profile places the business in Agricultural Inputs. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.
Latest available fiscal data shows $515.11M of revenue and -$49.88M of net income.
Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.
The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.
American Vanguard Corporation can be compared against peers such as Ascent Industries Co., Anfield Energy Inc. Common Shares, BioHarvest Sciences Inc. Common Stock, Bioceres Crop Solutions Corp., 5E Advanced Materials Inc., Fury Gold Mines Limited.
A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.
Current signals to investigate include market capitalization of $76.09M, beta of 1.44, and return on equity of -25.9%.
This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.
Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.
AVD currently shows total debt of $191.39M and beta of 1.44. Missing data should be treated as a research gap, not as low risk.
Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.
No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.
Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.
Recent filings to review: 3 (2026-06-05 00:00:00), 4 (2026-06-05 00:00:00), 4 (2026-06-05 00:00:00), 4 (2026-06-05 00:00:00).
Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.
Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.
Company website: https://www.american-vanguard.com
For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.